HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to control advanced breast cancer
Disease control Recruiting nowThis study tests a drug called alisertib combined with hormone therapy for people with a common type of advanced breast cancer (HR+, HER2-). The goal is to find the best dose and see if the combination can shrink tumors or slow the disease. About 150 adults whose cancer has worse…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Puma Biotechnology, Inc. • Aim: Disease control
Last updated May 17, 2026 11:54 UTC
-
New pill shows promise for Hard-to-Treat breast cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced HR+/HER2- breast cancer or other solid tumors that have spread. The main goal is to find the safest and most effective dose, either…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 17, 2026 11:37 UTC
-
New hope for advanced breast cancer: experimental drug EP0062 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called EP0062, alone or with standard treatments, in people with a certain type of advanced breast cancer (AR+/HER2-/ER+) that has come back or spread. The main goals are to find the safest dose and see if it helps shrink tumors. About 95 adu…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, lung, or ovarian cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors, either alone or combined with ot…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New Triple-Drug combo aims to control advanced breast cancer
Disease control Recruiting nowThis study tests a new drug called VS-6766 combined with two standard drugs (abemaciclib and fulvestrant) in people with advanced HR+/HER2- breast cancer that has spread. The goal is to find the safest dose and see if the combination helps control the cancer. About 63 participant…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New combo pill aims to outsmart BRCA breast cancer
Disease control Recruiting nowThis study tests whether adding a new oral drug (elacestrant) to standard olaparib can help people with a specific type of advanced breast cancer (HR+, HER2-, with BRCA1/2 mutations) live longer without the disease getting worse. About 176 participants will receive either the com…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
Timing matters: could your menstrual cycle change your breast cancer treatment?
Knowledge-focused Recruiting nowThis study looks at whether the phase of a woman's menstrual cycle affects a key cancer growth marker called Ki67 in early-stage, hormone-positive breast cancer. Researchers will also see if adding a genetic test (PAM50) helps doctors make better treatment decisions. About 504 wo…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Sponsor: University Hospital Tuebingen • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC